Keywords: Curis, Roche, Genentech, GDC-0449, Ovarian cancer, Hedgehog pathway

Roche tells Curis that Ph II data on GDC-0449 in advanced ovarian cancer needs additional investigation

Article | 10 August 2010

Print This

US drug developer Curis says that it has received preliminary results from a Phase II clinical trial of GDC-0449 from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in